Undecimal Bio
Developing AI-enabled targeted delivery of siRNA medicines beyond the liver for renovascular diseases.
Website: https://lnkd.in/dcbvZvh6
Cover Block
From the public record
| Field | Value |
|---|---|
| Name | Undecimal Bio |
| Tagline | Developing AI-enabled targeted delivery of siRNA medicines beyond the liver for renovascular diseases. |
| Headquarters | Cambridge, England |
| Founded | 2025 |
| Stage | Seed |
| Business model | B2B |
| Industry | Deeptech |
| Technology | Biotech / Life Sciences |
| Geography | Western Europe |
| Growth profile | Venture Scale |
| Founding team | Co-Founders (2) |
| Funding label | Seed |
| Total disclosed | ~$18,000,000 [Business Wire, October 2026] |
Links
From the public record
The Short Version
PUBLIC Undecimal Bio is building targeted delivery for siRNA medicines beyond the liver, a technically important bottleneck in RNA therapeutics, and it merits investor attention now because it launched with an $18 million seed round in October 2026 and a syndicate led by specialist life sciences backers [Business Wire, October 2026] [CTech, October 2026]. The company was founded in 2025 in Cambridge, England, and described at launch as a spin-out from Eleven Therapeutics, with operations also cited in Tel Aviv, which gives the story a clearer translational lineage than a typical first-time platform company [Business Wire, October 2026] [CTech, October 2026].
Its core platform, DELiveri®, is presented as an AI-enabled system for identifying conjugates that can direct RNA medicines to defined cell types, with the initial internal focus on renovascular disease, where management argues current siRNA approaches are constrained by the field's concentration in liver delivery [Business Wire, October 2026] [Clinical Renal Associates]. The differentiation claim rests less on a named asset in clinic and more on treating delivery as a data problem, which could be meaningful if the platform produces repeatable tissue-targeting results beyond the liver, but that remains to be shown in public data [LinkedIn] [Business Wire, October 2026].
The founding team combines scientific and company-building history around the same ecosystem: Dr. Yaniv Erlich has been identified publicly as a co-founder of Eleven Therapeutics and its CEO, and previously served as Chief Scientific Officer of MyHeritage DNA, while Shaul Ilan is named as co-founder and a long-time partner of Erlich in public investor commentary [Kenes Exhibitions] [mAcademia podcast] [Cold Spring Harbor Laboratory] [LinkedIn]. On financing, the company announced an oversubscribed $18 million seed co-led by 4BIO Capital and IQ Capital, with participation from Verve Ventures, Harel Tech, Entrée Capital, Kerna Ventures, and Saras Capital, and the stated model appears oriented toward B2B value creation through platform development and potential pharma collaboration rather than near-term product revenue [Business Wire, October 2026].
Over the next 12 to 18 months, the public markers to watch are whether Undecimal can move from platform description to disclosed preclinical evidence, name any external research partners, and show that its delivery approach has utility outside a narrow proof-of-concept setting [Business Wire, October 2026]. The round size and investor set indicate early conviction, but most operating claims remain company-sourced at launch, so the central diligence question is whether the biology will mature into independently visible validation.
Single-source, plausible -- Section relies on one independent news report and multiple company-sourced launch claims, with partial corroboration from public biographies and secondary coverage.
Taxonomy Snapshot
| Axis | Value |
|---|---|
| Stage | Seed |
| Business Model | B2B |
| Industry / Vertical | Deeptech |
| Technology Type | Biotech / Life Sciences |
| Geography | Western Europe |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (2) |
| Funding | Seed, total disclosed ~$18,000,000 |
The Company in Brief
PUBLIC
Undecimal Bio entered the public record with a narrow and technically specific pitch: targeted delivery of siRNA medicines beyond the liver, beginning with renovascular disease programs [Business Wire, October 2026]. The company is headquartered in Cambridge, England, was founded in 2025, and describes itself as a spin-out from Eleven Therapeutics [Business Wire, October 2026]. Public source material also ties part of the operating footprint to Tel Aviv, although the Cambridge headquarters is the clearest confirmed base in the available record [CTech, October 2026].
The chronology is short but legible. In October 2026, Undecimal launched publicly alongside an $18 million seed financing co-led by 4BIO Capital and IQ Capital, with participation from Verve Ventures, Harel Tech, Entrée Capital, Kerna Ventures, and Saras Capital [Business Wire, October 2026]. The same announcement identified co-founders Dr. Yaniv Erlich and Shaul Ilan and framed the new company around an AI-enabled delivery platform called DELiveri®, with early work aimed at renovascular disease rather than a broad multi-indication story at launch [Business Wire, October 2026].
Single-source, plausible -- This section relies primarily on the October 2026 launch announcement, with partial corroboration from CTech on headquarters footprint and spin-out status.
What They Have Built
MIXED
The technical claim worth isolating is narrow but consequential: Undecimal Bio says it is building targeted delivery for small-interfering RNA medicines outside the liver, a constraint the company describes as the "liver trap" in current siRNA delivery [Business Wire, October 2026]. In plain terms, the company is not presenting itself as a general RNA therapeutics developer, but as a delivery-layer company whose first application is renovascular disease, a category involving the renal arteries that supply blood to the kidneys [Business Wire, October 2026] [Clinical Renal Associates].
The core platform, DELiveri®, is described by the company as a proprietary, AI-enabled system for identifying conjugates that direct RNA medicines to defined cell types [Business Wire, October 2026]. That framing is directionally interesting because it treats delivery as a targeting and data problem rather than only a chemistry problem, a view also reflected in co-founder Shaul Ilan's LinkedIn description [LinkedIn, retrieved 2026]. Still, the public record here remains early: there is no verified demo, no disclosed preclinical dataset, no named pharma partner, and no public technical detail on model architecture, screening workflow, or validation results in the cited materials [Business Wire, October 2026] [LinkedIn, retrieved 2026].
A few operational details do sharpen the picture. Launch coverage says the company spun out of Eleven Therapeutics and plans to use its seed financing to further develop DELiveri and expand the team at laboratories based at the Cancer Research UK Cambridge Institute [Business Wire, October 2026] [CTech, October 2026]. That suggests a platform company still in buildout, with the technology case resting more on founder and investor credibility than on publicly inspectable performance data at this stage [Business Wire, October 2026].
Unconfirmed -- Product claims are primarily company-sourced via Business Wire, with limited corroboration from CTech and LinkedIn and no public technical validation data.
Market Size and Demand
PUBLIC
The market matters now because RNA therapeutics have proved they can reach patients, but extrahepatic delivery remains a gating constraint on how much of that platform value can move beyond liver biology [Business Wire, October 2026].
Undecimal is pursuing a narrow problem inside a large and still shifting therapeutic stack: how to direct siRNA medicines to cell types outside the liver, with an initial focus on renovascular disease [Business Wire, October 2026]. Public sources supplied for this report do not include a cited third-party TAM, SAM, or SOM for extrahepatic siRNA delivery, targeted RNA conjugates, or renovascular siRNA therapeutics specifically. That absence matters because it limits precision on market sizing, and it pushes the analysis toward demand conditions rather than revenue math.
The clearest demand driver in the available record is technical, not commercial. The company's launch materials frame the current bottleneck as the "liver trap," meaning siRNA delivery remains concentrated in the liver and therefore constrains use in other organs [Business Wire, October 2026]. If that description is directionally right, the spend opportunity sits upstream of any single indication: a delivery platform that expands tissue reach could matter to internal pipelines, partnered programs, and broader RNA drug development budgets, even before one disease area is clinically de-risked [Business Wire, October 2026].
A second tailwind is that the buyer set appears legible, at least in outline. Business Wire reported that Undecimal had already entered several research collaborations with large pharmaceutical companies, although no counterparties were named [Business Wire, October 2026]. That does not establish recurring platform revenue or durable demand, but it does suggest that large-cap pharma is at least willing to evaluate delivery-enablement tools in this category.
| Market lens | Public evidence | Read-through for demand |
|---|---|---|
| Core problem area | siRNA delivery is described as heavily concentrated in the liver, limiting treatment of diseases in other organs [Business Wire, October 2026] | Delivery remains a bottleneck market rather than a solved infrastructure layer |
| Initial disease wedge | Undecimal is initially applying its platform to renovascular diseases [Business Wire, October 2026] | The first commercial path may be indication-led, even if the platform ambition is broader |
| Adjacent buyer universe | The company reported several research collaborations with big pharma companies, without naming them [Business Wire, October 2026] | Potential counterparties likely include pharma R&D groups evaluating RNA delivery tools |
| Disease context | Renovascular disease primarily affects the renal arteries that deliver blood to the kidneys [Clinical Renal Associates] | The initial wedge points toward renal and vascular biology rather than liver-directed RNA medicine |
The table points to a market that is easier to describe strategically than to size cleanly from public evidence. The investable question is less about headline TAM at this stage and more about whether delivery into kidney-adjacent and vascular tissues can become reproducible enough to support programs, partnerships, or both.
Adjacent markets are also relevant because Undecimal's platform positioning could pull it beyond a single renal application if the delivery data generalizes. The nearest adjacencies implied by the sources are broader RNA therapeutics, conjugate discovery, and platform partnerships with pharmaceutical companies working on non-hepatic indications [Business Wire, October 2026]. Substitute approaches would include other methods for tissue targeting in RNA medicine, although the provided public sources do not name specific modalities or vendors, so any tighter segmentation would exceed the evidence base.
Regulation and macro conditions cut both ways. On the positive side, RNA therapeutics remains a category where platform improvements can create outsized option value if they improve tissue specificity or widen the set of addressable organs, which helps explain investor appetite for a seed syndicate anchored by specialist life sciences funds [Business Wire, October 2026]. On the limiting side, this is still a biotech platform market where value realization is likely to depend on preclinical proof, translational reproducibility, and eventually regulatory acceptance of delivery constructs, none of which can be inferred from a financing announcement alone [Business Wire, October 2026].
Single-source, plausible -- This section rests primarily on the October 2026 launch announcement, with limited independent context from Clinical Renal Associates on renovascular disease anatomy.
Who Else Is Fighting for This
MIXED Undecimal Bio is positioning itself against a bottleneck in RNA therapeutics rather than against a named, publicly disclosed peer set, which makes the early competitive question less about share capture and more about whether its delivery approach can become a credible option for partners trying to move siRNA beyond the liver [Business Wire, October 2026].
The public record supports only a narrow competitive map. On one side sit established RNA-therapeutics programs whose delivery has historically concentrated in the liver, the problem Undecimal itself calls the "liver trap" [Business Wire, October 2026]. On another side are platform developers working on targeted delivery as an enabling layer for nucleic acid medicines, although the supplied sources do not name direct rivals, specific programs, or comparative clinical data [CTech, October 2026]. A third category is the substitute set: companies and drug programs that address renovascular disease or adjacent renal biology without using siRNA delivery beyond the liver, which matters because Undecimal's initial wedge is not a broad RNA platform sale but an application in renovascular disease [Business Wire, October 2026; Clinical Renal Associates].
That leaves Undecimal with a defensible edge that is interesting but still mostly company-described. The company says its DELiveri® platform is proprietary and AI-enabled, and that it treats delivery as a data problem, a framing that implies differentiation could come from conjugate-discovery data and selection methods rather than from a single asset [Business Wire, October 2026; LinkedIn]. If that dataset compounds through research collaborations and internal experiments, the edge could become durable. If it remains a promising platform story without externally visible validation, it is perishable, because larger RNA companies and better-capitalized platform teams can fund similar discovery work over time [Business Wire, October 2026].
The clearest exposure is evidence, not concept. 4BIO Capital and IQ Capital bring financing credibility through the seed round, and Undecimal's spin-out status from Eleven Therapeutics gives it a scientific origin story, but neither point substitutes for disclosed partner names, preclinical benchmarks, or proof that cell-type targeting translates into therapeutically relevant delivery in renovascular disease [Business Wire, October 2026; CTech, October 2026]. In practical terms, the company is most exposed to any named RNA therapeutics developer or delivery platform company that can show organ-specific delivery data in public before Undecimal does. The sources provided simply do not identify that rival by name, which limits how far a fair public comparison can go.
The most plausible 18-month scenario is that financing quality, founder credibility, and a crisp problem statement keep Undecimal competitive for early pharma conversations, while the field sorts on validation milestones rather than branding [Business Wire, October 2026; Cold Spring Harbor Laboratory; mAcademia podcast]. Winner if X: Undecimal, if it can convert the current platform narrative into disclosed collaborations or data that show reproducible delivery beyond the liver in its initial renovascular focus [Business Wire, October 2026]. Loser if Y: Undecimal, if competing RNA-delivery efforts, named publicly elsewhere but not in the supplied record, produce stronger validation first and leave Undecimal competing as one more early discovery platform without a visible proof point.
Inferred, not confirmed -- Core competitive positioning is grounded in Business Wire and CTech, but the supplied record names no direct competitors and offers no independent comparative performance data, so parts of the mapping are necessarily inference-based.
Opportunity
Upside Case
PUBLIC The prize here is not a single renal program, but a credible shot at becoming a preferred delivery layer for RNA medicines that need to reach cell types outside the liver, one of the better-defined bottlenecks in the field according to the company launch materials and follow-on coverage [Business Wire, October 2026] [CTech, October 2026].
The headline opportunity is straightforward. If Undecimal Bio can show that its DELiveri platform reliably identifies conjugates that direct siRNA medicines to defined cell types, it could matter well beyond its initial renovascular focus because the underlying constraint it is targeting is a platform problem, not a one-indication problem [Business Wire, October 2026]. That does not make success likely, and the technical claims remain company-led, but the framing is at least coherent: current siRNA delivery is heavily concentrated in the liver, and Undecimal is explicitly organized around pushing RNA delivery beyond that limit [Business Wire, October 2026] [CTech, October 2026]. The presence of a specialist syndicate co-led by 4BIO Capital and IQ Capital, alongside participation from Verve Ventures, Harel Tech, Entrée Capital, Kerna Ventures, and Saras Capital, is not proof of platform validity, but it does suggest the company has raised enough capital to attempt a real proof cycle rather than a narrow academic experiment [Business Wire, October 2026].
A reasonable upside framework is less about one binary drug outcome and more about which commercialization path matures first. The table below sets out three distinct ways this could scale if the early science translates.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Platform partner for extra-hepatic RNA delivery | Undecimal becomes a repeat collaboration partner for pharma teams developing siRNA assets that need delivery beyond the liver | A disclosed research or platform partnership with a large pharmaceutical company | The company said it has already entered several research collaborations with big pharma companies, although none were named publicly [Business Wire, October 2026] |
| Renovascular wedge, broader renal franchise | The first validated use case is renovascular disease, then the company applies the same delivery logic to additional kidney-related targets and cell types | Early preclinical data in renovascular models that show tissue-specific delivery or functional knockdown | Undecimal said it is initially applying DELiveri to renovascular diseases, a category tied to the renal arteries and kidney blood supply [Business Wire, October 2026] [Clinical Renal Associates] |
| Delivery engine spun out of Eleven becomes a standalone platform company | The market begins to treat Undecimal less like a single-asset biotech and more like an enabling platform that can generate multiple programs and partners | Repeatability across more than one organ or disease area | The company is a spin-out from Eleven Therapeutics and describes DELiveri as a platform for identifying conjugates that direct RNA medicines to defined cell types, which is a broader claim than a single program thesis [Business Wire, October 2026] [CTech, October 2026] |
The compounding logic, if it works, would come from data accumulation and partner adjacency rather than classical network effects. Management describes delivery as a data problem, and the DELiveri platform is presented as AI-enabled, which implies that each successful conjugate-design cycle could improve future search efficiency across cell types and disease contexts [LinkedIn] [Business Wire, October 2026]. That remains a company thesis, not an independently validated moat, but it is the right kind of moat for this category: if one program yields better delivery data, the next program can start from a stronger prior. The other compounding vector is commercial. Undecimal has publicly referenced several research collaborations with big pharma companies, and if even a subset convert into deeper platform relationships, credibility with one partner can reduce adoption friction with the next [Business Wire, October 2026].
The size of the win is hard to pin down from public evidence because no external market-sizing source or direct public comparable was supplied in the research set. Even so, the shape of the upside is still legible. In the strongest scenario, not a forecast, Undecimal could become a strategically relevant RNA-delivery platform with both internal programs and external partnerships, which would place it in the part of biotech where value is driven by platform optionality as much as by a single asset. The $18 million seed financing announced at launch is small relative to that endpoint, but it is enough to fund an initial attempt at demonstrating repeatable delivery beyond the liver and to expand the team around the Cambridge research base, according to the company announcement [Business Wire, October 2026]. The public case therefore rests on one proposition: if extra-hepatic siRNA delivery proves tractable and programmable, the company may have started in a narrow wedge but is aiming at a much larger control point in RNA therapeutics [Business Wire, October 2026] [Startup.eu, October 2026].
Unconfirmed -- This section relies materially on company-announced product and partnership framing from Business Wire, with limited independent corroboration from CTech and Startup.eu, and no independent public validation yet of the core platform claims or upside economics.
Sources
From the public record
[Business Wire, October 2026] Undecimal Bio launches with $18 million oversubscribed Seed financing to address ‘liver trap’ in siRNA therapeutic delivery | https://www.businesswire.com/news/home/20261013517369/en/Undecimal-Bio-launches-with-18-million-oversubscribed-Seed-financing-to-address-liver-trap-in-siRNA-therapeutic-delivery
[CTech, October 2026] Undecimal Bio raises $18 million Seed to tackle a key obstacle in RNA medicines | https://www.calcalistech.com/ctechnews/article/hjyfaviszg
[Clinical Renal Associates] Renovascular Hypertension and Ischemic Nephropathy | https://www.clinicalrenal.com/renovascular-hypertension-and-ischemic-nephropathy/
[LinkedIn, retrieved 2026] Shaul Ilan - ScionxBio | LinkedIn | https://www.linkedin.com/in/shaul-ilan-8064bb51/
[Kenes Exhibitions, retrieved 2026] Daily Program - Biomed 2024 | https://kenes-exhibitions.com/biomed2024/?page_id=1647
[mAcademia podcast, retrieved 2026] #51 - Science is exciting no matter where you do it - with Yaniv Erlich from Eleven Therapeutics | https://www.macademiapodcast.com/51-science-is-exciting-no-matter-where-you-do-it-with-yaniv-erlich-from-eleven-therapeutics/
[Cold Spring Harbor Laboratory, retrieved 2026] Base Pairs Episode 17.5: Special interview with Yaniv Erlich | https://www.cshl.edu/podcasts/episode-17-5-special-interview-with-yaniv-erlich/
[Startup.eu, October 2026] Cambridge siRNA delivery startup Undecimal Bio launches with oversubscribed $18 million seed round | https://www.startup.eu/
Articles about Undecimal Bio
- Undecimal Bio's $18 Million Seed Takes siRNA Beyond the Liver Trap — The Cambridge biotech is using its DELiveri platform to direct RNA therapies to renovascular diseases, a first step beyond the liver.